Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been demonstrated to induce cell apoptosis in many types of tumors, while many hepatocellular carcinoma (HCC) cells display high resistance to TRAIL. Another outstanding limitation of TRAIL is the short half-life in vivo. Stem cell-based therapies provide a promising approach for the treatment of many types of tumors because of the ability of tropism. Therefore, as a new therapeutic strategy, the combination of chemotherapeutic agents and TRAIL gene modified MSCs (TRAIL-MSCs) would improve the therapeutic efficacy of HCC in vivo. This is the first time to show the potential of combination of chemotherapeutic agents and MSCs as a gene vector in the therapy of HCC.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Apoptosis / drug effects
-
Carcinoma, Hepatocellular* / drug therapy
-
Carcinoma, Hepatocellular* / genetics
-
Carcinoma, Hepatocellular* / pathology
-
Cell Line, Tumor
-
Cisplatin / administration & dosage*
-
Drug Resistance, Neoplasm / genetics*
-
Flow Cytometry
-
Gene Expression Regulation, Neoplastic / drug effects
-
Genetic Therapy
-
Humans
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / genetics
-
Liver Neoplasms / pathology
-
Mesenchymal Stem Cell Transplantation*
-
Mesenchymal Stem Cells / cytology
-
Mesenchymal Stem Cells / metabolism
-
Mice
-
TNF-Related Apoptosis-Inducing Ligand* / genetics
-
TNF-Related Apoptosis-Inducing Ligand* / metabolism
-
Transplantation, Heterologous
Substances
-
Antineoplastic Agents
-
TNF-Related Apoptosis-Inducing Ligand
-
TNFSF10 protein, human
-
Cisplatin